Alpiropride

Alpiropride
Clinical data
Trade names	Revistel, Rivistel, or Rivestel
Other names	Iristel; RIV-2093; RIV2093; RIV 2093; Riv 2093; Riv-2093; Riv2093
Drug class	DopamineD2receptorantagonist;Antihypertensive agent;Antimigraine agent
Identifiers
	IUPAC name 4-amino-2-methoxy-5-(methylsulfamoyl)-N-[(1-prop-2-enylpyrrolidin-2-yl)methyl]benzamide;
CAS Number	81982-32-3;
PubChemCID	71253;
ChemSpider	64384;
UNII	1768UW0XS1;
ChEBI	CHEBI:135599;
ChEMBL	ChEMBL2104024;
CompTox Dashboard(EPA)	DTXSID30868635;
ECHA InfoCard	100.072.585
Chemical and physical data
Formula	C17H26N4O4S
Molar mass	382.48g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CNS(=O)(=O)C1=C(C=C(C(=C1)C(=O)NCC2CCCN2CC=C)OC)N;
	InChI InChI=1S/C17H26N4O4S/c1-4-7-21-8-5-6-12(21)11-20-17(22)13-9-16(26(23,24)19-2)14(18)10-15(13)25-3/h4,9-10,12,19H,1,5-8,11,18H2,2-3H3,(H,20,22); Key:QRQMZZNDJGHPHZ-UHFFFAOYSA-N;

Alpiropride(INNTooltip International Nonproprietary Name;brand nameRevistel,Rivistel,orRivestel) is adopamine D₂receptor antagonistof thebenzamidegroup related tosulpiride.^[1]^[2]^[3]^[4]^[5]It is described as anantihypertensive agentand has been marketed for use as anantimigraine medicationinPortugal.^[1]^[4]^[2]The drug was first described by 1980^[1]and was introduced for medical use by 1989.^[4]It remained marketed in Portugal as late as 2000.^[2]